You are here: Industry Insights > Market News > Eris Lifesciences Q2 net up 35 per cent at Rs 93.14 cr

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Retatrutide 2381089-83-2

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

Eris Lifesciences Q2 net up 35 per cent at Rs 93.14 cr

expressbpdNovember 20, 2017

Tag: Eris , LifeSciences

Favorites

Consolidated total income of the company also rose to Rs 255.68 crore

Drug firm Eris Lifesciences has reported a 34.51 per cent rise in its consolidated net profit to Rs 93.14 crore for the second quarter ended September 30. The company had posted a net profit of Rs 69.24 crore for the corresponding period of the previous fiscal, Eris Lifesciences said in a filing to BSE. Consolidated total income of the company also rose to Rs 255.68 crore for the quarter under consideration as against Rs 208.08 crore for the same period a year ago.

Previous:Statement by FDA Commissioner Scott Gottlieb, M.D., on efforts to address impact of IV fluid shortag

Next:Strides Shasun divests India brand business to Eris Lifesciences for Rs 500 cr

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

PRNewswireDecember 18, 2024

Seoul 120 hotline has contributed to efficient city operation, according to the Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024) released on Wednesday.

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

Eris Lifesciences Q2 net up 35 per cent at Rs 93.14 cr | Pharmasources.com

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

Eris Lifesciences Q2 net up 35 per cent at Rs 93.14 cr

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

You may like
More>>

Eris Lifesciences Q2 net up 35 per cent at Rs 93.14 cr

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

You may likeMore>>

You may like
More>>